>> Anything that is injected in the vitreous is rapidly washed out (think of Genentech and Eyetech intravitreal administration). <<
I think you are being too dismissive of Macugen and Lucentis. These drugs worked pretty well in their mid-stage trials. And PFE, NVS, and DNA would not be spending big money to test them in large phase-3 trials if the drugs were simply washed out of the vitreal chamber before they could accomplish anything.
Evidently, Macugen and Lucentis are able to bind to their receptors with sufficient affinity and duration to have a therapeutic effect.
Market Data 
Markets 
AI
